MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharina, I. G.
Right arrow Articles by Goldman, I. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharina, I. G.
Right arrow Articles by Goldman, I. D.

Vol. 59, Issue 5, 1022-1028, May 2001

Mutational Analysis of the Functional Role of Conserved Arginine and Lysine Residues in Transmembrane Domains of the Murine Reduced Folate Carrier

Iraida G. Sharina, Rongbao Zhao, Yanhua Wang, Solomon Babani, and I. David Goldman

Department of Integrative Biology, and the Institute of Molecular Medicine, University of Texas, Houston, Texas (I.G.S.); and Departments of Medicine and Molecular Pharmacology and the Albert Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York (R.Z., Y.W., S.D., I.D.G.)

The reduced folate carrier (RFC1) plays a major role in the delivery of folates into mammalian cells. RFC1 is an anion exchanger with seven conserved positively charged amino acid residues within 12 predicted transmembrane domains. This article explores the role of these residues in transport function by the development of cell lines in which arginines and lysines in RFC1 were replaced with leucine by site-directed mutagenesis. Three cell lines transfected with R131L, R155L, or R366L all lacked activity, despite high levels of protein expression in the plasma membrane, suggesting the crucial role of these amino acid residues in RFC1 function. In several mutant carriers, R26L, R42L, and K332L, there was little or no change in the influx Kt value for MTX or influx Ki value for folic acid. However, the R26L, R42L, and K332L carriers had decreased affinity for reduced folates. This was most prominent for K404L, which had 11- and 4-fold increases in influx Ki for 5-methyl-THF and 5-formyl-THF, respectively, compared with L1210 cells. The marked influx stimulation observed with wild-type carrier when extracellular chloride was decreased was significantly diminished when influx was mediated by the K404L carrier, but was only slightly decreased with the R26L, R42L, and K332L mutants. This suggested that the K404 residue may be a major site of inhibition by chloride in the wild-type carrier. These studies indicate the important role that some positively charged residues within transmembrane domains of RFC1 play in RFC1 function.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
Y. Deng, Z. Hou, L. Wang, C. Cherian, J. Wu, A. Gangjee, and L. H. Matherly
Role of Lysine 411 in Substrate Carboxyl Group Binding to the Human Reduced Folate Carrier, as Determined by Site-Directed Mutagenesis and Affinity Inhibition
Mol. Pharmacol., April 1, 2008; 73(4): 1274 - 1281.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Hou, J. Ye, C. L. Haska, and L. H. Matherly
Transmembrane Domains 4, 5, 7, 8, and 10 of the Human Reduced Folate Carrier Are Important Structural or Functional Components of the Transmembrane Channel for Folate Substrates
J. Biol. Chem., November 3, 2006; 281(44): 33588 - 33596.
[Abstract] [Full Text] [PDF]

Home page
 Biophys. JHome page
L. P. Shank, J. R. Broughman, W. Takeguchi, G. Cook, A. S. Robbins, L. Hahn, G. Radke, T. Iwamoto, B. D. Schultz, and J. M. Tomich
Redesigning Channel-Forming Peptides: Amino Acid Substitutions that Enhance Rates of Supramolecular Self-Assembly and Raise Ion Transport Activity
Biophys. J., March 15, 2006; 90(6): 2138 - 2150.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Hou, S. E. Stapels, C. L. Haska, and L. H. Matherly
Localization of a Substrate Binding Domain of the Human Reduced Folate Carrier to Transmembrane Domain 11 by Radioaffinity Labeling and Cysteine-substituted Accessibility Methods
J. Biol. Chem., October 28, 2005; 280(43): 36206 - 36213.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. L. Witt, S. E. Stapels, and L. H. Matherly
Restoration of Transport Activity by Co-expression of Human Reduced Folate Carrier Half-molecules in Transport-impaired K562 Cells: LOCALIZATION OF A SUBSTRATE BINDING DOMAIN TO TRANSMEMBRANE DOMAINS 7-12
J. Biol. Chem., November 5, 2004; 279(45): 46755 - 46763.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
C. Kneuer, K. U. Honscha, and W. Honscha
Sodium-dependent methotrexate carrier-1 is expressed in rat kidney: cloning and functional characterization
Am J Physiol Renal Physiol, March 1, 2004; 286(3): F564 - F571.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
H. Sadlish, F. M. R. Williams, and W. F. Flintoff
Functional Role of Arginine 373 in Substrate Translocation by the Reduced Folate Carrier
J. Biol. Chem., October 25, 2002; 277(44): 42105 - 42112.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. Balamurugan and H. M. Said
Functional role of specific amino acid residues in human thiamine transporter SLC19A2: mutational analysis
Am J Physiol Gastrointest Liver Physiol, July 1, 2002; 283(1): G37 - G43.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics